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ABSTRACT
Objective: The objective of the study was to evaluate the safety and efficacy of antiurolithic herbal formula (AHF) compared with commercial 
polyherbal lithotriptic (CPL) agent in urolithiasis subjects.
 Materials and Method: The study was conducted with the design of purposive randomized open-label, end-blinded observation. The sample size 
and randomization were done by computer with generated statistical program. The total of subjects who met the inclusion and exclusion criteria 
was 200 patients. Every subject was given AHF or CPL according to their group and the intervention was carried out for 8 weeks. The study used the 
difference of stone’s size and number as parameter to observe the efficacy between two groups. While in terms of safety, this study used biochemical 
parameters of liver and kidney function.
Results: A total of 191 adult patients with urolithiasis were enrolled. There were 97 and 94 subjects in AHF and CPL group, respectively. The study 
showed a significant size reduction of single’s and multiple’s stone in AHF group (p<0.05). The size reduction difference in AHF group is greater than 
in CPL group. The number of multiple stone’s subjects who treated AHF was significantly decreased. Whereas in CPL group, there was no significant 
size difference between pre and Post treatment. The biochemical parameters showed normal liver and renal function in both groups.
Conclusion: This study result indicates that AHF is safe and effective in the treatment of urolithiasis.
Keywords: Antiurolithic, Herbal, Formula, Clinical study.
INTRODUCTION
Urolithiasis is the third most common urinary system disease in medical 
service [1-3]. Incidence of urolithiasis can be occurred in 10–12% of the 
population in developed countries with the highest age at 20–40 years [4]. 
It is more frequent in men than woman [5] which has High recurrence 
rate about 50% (5-10 years) and 75% (20 years) [6]. The underlying 
mechanism of urolithiasis can be explained as an imbalance between 
promoting and inhibitory component of stone formation in urine [3]. 
Based on Riskesdas, 2013, the prevalence of urolithiasis diagnosed by 
physician was 0.6% [7]. Urolithiasis can be found in the form of calcium, 
cystine, uric acid, or struvite stones. About 75% of urolithiasis consists 
of calcium salts which observed as calcium oxalate (50%), calcium 
phosphate (5%), and mixture of both (45%) [1]. The first crystal in the 
loop of Henle or in the distal tubule was calcium phosphate. Excess of 
reactive oxygen species had important role in injury and inflammation 
of epithelial renal. Furthermore, it leads to the formation of stones when 
generated uncontrollably [8].
Extracorporeal shock wave lithotripsy is one of the standard procedures 
for eliminating nephrolithiasis. Although it is claimed safe, it still has 
negative effects such as traumatic effect of shock waves, decreasing 
renal function, the possibility of infection, or persistent stone fragments 
residue that consequences of increasing stone recurrence [9]. Therefore, 
there is an advanced idea to find another treatment to complete these 
methods using phytotherapy which can be considered as suitable long-
term treatment for urolithiasis [10,11]. Hence, it is necessary to get 
antilithiatic drugs from herbal remedies with minimal side effect. Due to 
their efficacy and low toxicity, it could be the best alternative choice [12].
Several studies showed antilithiatic effect of medicinal plant such as 
Strobilanthes crispa L. Blume, Orthosiphon stamineus, Sonchus arvensis L., 
and Imperata cylindrica. Some of them have been proved about their 
therapeutic potential in vitro models [12,13]. The result of preliminary 
study of urolithiasis formula which is consist of S. crispa L. Blume, O. 
stamineus, S. arvensis L., and I. cylindrica, Curcuma longa, Curcuma 
xanthorrhiza, and Phyllanthus niruri revealed that size of stone can be 
reduced in the treatment and positive control compared to negative 
control group  [13]. Furthermore, the aim of this study was to evaluate 
the safety and efficacy of antilithiatic formula in urolithiasis subjects. 
MATERIALS AND METHODS 
Study design
This study was conducted at medicinal plant and traditional medicine 
research and development center (B2P2TOOT), Ministry of Health, 
Indonesia. The study was carried out by 70 physicians and 20 
pharmacists who had been trained about traditional medicinal services. 
The study design was purposive randomized open-label, end-blinded 
observation. The randomization sequence was computer generated. The 
investigators were blinded to treatment allocation. The total of subjects 
who met the inclusion and exclusion criteria was 200 patients [14]. 
Subjects were randomly divided into two groups which are antiurolithic 
herbal formula (AHF) group and commercial polyherbal lithotriptic 
(CPL) group. Laboratory and radiology examination used the accredited 
laboratories. Blass nier overzicht (BNO) and ultrasound result were 
reported by independent radiologist. This study had been approved 
by The Ethics Commission of National Institute of Health Research and 
Development, Health Ministry Republic of Indonesia (LB.02.01/5.2/KE 
063/2016) on March 13, 2017.
Preparation of materials
In AHF group, each subject was given herbal formula which 
consisted of dried simplisia of 10 g S. arvensis, 6 g O. stamineus, 4 g 
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Strobilanthes crispus, 5 g Imperata cylindrica, 5 g C. xanthorrhiza, 4 g 
Curcuma domestica, and 3 g P. niruri. Before being administered to the 
subject, the simplisia was managed and controlled by Post Harvest 
Division, B2P2TOOTTawangmangu Indonesia.
AHF was prepared boiling 1 L of water, then put simplisia in boiling 
water for 15 min. Subjects were instructed to drink the filtered water 
twice a day after breakfast and dinner for 8 weeks.
The subjects in control group consumed CPL which consisted of the 
extract of O. stamineus 18 mg, S. crispa L. Blume 6 mg, S. arvensis L. 
24 mg, and P. niruri 2.4 mg and Plantago major 100 mg. Control’s group 
received one capsule for 4 times daily.
Inclusion and exclusion criteria
Urolithiasis subjects with <20 mm stone size, with or without clinical 
symptoms such as pain in the renal angle or flanks to the groin, urinary 
disturbance, and radiopaque stone through X-ray examination or 
ultrasound were included in the study. In the other hand, subject with 
a history of hypersensitivity of herbal formula, severe urinary tract 
infection, Grade III–IV hydronephrosis through ultrasonography (USG) 
or BNO, diabetes mellitus, creatinine >2 gr/dl, and pregnant women. 
Before the intervention, they were examined about clinical symptoms, 
size of urinary tract stone by USG, visual analog scale (VAS), liver and 
renal function (serum glutamic-oxaloacetic transaminase [SGOT], 
serum glutamic-pyruvic transaminase [SGPT], blood urea nitrogen 
[BUN], and creatinine), and kalium.
Parameter of efficacy and safety
Subjects were observed about their clinical symptoms using VAS assess 
pain degree. VAS was checked at baseline, 4th week, and 8th week of 
intervention. All subjects were evaluated their size of urolithiasis at 
baseline and the end of study (8th week) by ultrasound.
The safety parameters were evaluated by examined SGOT, SGPT, BUN, 
and creatinine to asses liver and renal function at baseline, 4th week, 
and 8th week. In addition, other biochemical parameters (kalium) 
were also measured at baseline and the end of study (8th weeks). The 
minimum of clinical outcome of this study was the reduction of stone 
size more than 50% comparing with baseline. Furthermore, the stone 
was disappeared in 8 weeks.
All adverse events during treatment were recorded and evaluated. Side 
effect was obtained based on interview and observation of the subject 
and also through laboratory tests: Renal (BUN and creatinine) and liver 
function (SGOT and SGPT).
Statistical analyses
The data were analyzed statistically using a software program for 
statistical analysis version 18.0. Descriptive data were calculated and 
presented as table to assess demographic characteristic, size, and 
number of stone, VAS and biochemical parameters. Data analysis was 
used t-paired t-test to see the difference before and after treatment 
and independent t-test to see the difference between two groups. The 
Wilcoxon test for paired test and Mann–Whitney U-test was used where 
there is an abnormal data distribution on Kolmogorov–Smirnov test 
result. 
RESULTS
A total of 307 adult urolithiasis patients screened, we enrolled 200 
subjects. As much 200 subjects were randomized to AHF and CPL group. 
Fig. 1 show that in AHF group, there were three dropped out subjects 
due to resigned and out of town. In CPL group, six subjects were dropped 
out of the study due to resign (4) and lost of follow-up (2). At baseline, 
Table 3 also shows there was no significant difference (p>0.05) in 
demographic data, for example, age, sex, education, occupation, and body 
mass index (BMI) between AHF and CPL group. Baseline characteristics 
were similar in the two groups and shown in Table 1. 
Table 2 shows that 85% and 83% of stone is found at pelvis renalis in 
AHF and CPL group, respectively. Subjects who had vesicolithiasis were 
5.1% and 3.1% in formula and CPL group, respectively. The most type 
of stone was single stone in AHF group whereas also in CPL group. 
The total number of stone before treatment between two groups was 
similar and had no significant difference (p>0.05). There was also no 
significant difference on the size of single and multiple of stone between 
two groups.
Table 1: The demographic characteristics of formula and CPL group
Characteristics AHF group n (%) CPL group n (%) Total n p
Age 0,412
17–25 yr 3 (3.09) 0 3
26–35 yr 11 (11.34) 12 (12.77) 23
36–45 yr 20 (20.62) 24 (25.53) 44
45–55 yr 46 (47.42) 44 (46.81) 90
>55 yr 17 (17.53) 14 (14.89) 31
Sex 0.643
Men 64 (65.98) 59 (62.77) 123
Woman 33 (34.02) 35 (37.23) 68
Education (finished) 0.312
Elementary of school 17 (17.53) 26 (27.66) 43
Junior high school 13 (13.40) 9 (9.27) 22
Senior high school 31 (31.96) 31 (32.98) 62
University 36 (37.11) 28 (29.79) 64
Occupation 0.355
Retired 14 (14.43) 9 (9.57) 55
Military/Police/Officer 19 (19.59) 27 (28.72) 46
Private Employee 13 (13.40) 19 (20.21) 32
Entrepreneur 21 (21.65) 14 (14.89) 35
Labor/farmer/fisherman 17 (17.53) 13 (13.83) 30
Others job 13 (13.40) 12 (12.77) 25
BMI 0.496
Underweight 3 (3.09) 6 (6.38) 9
Normal weight 43 (44.33) 37 (39.36) 80
Overweight 42 (43.30) 42 (44.68) 84
Obesity I 8 (8.25) 8 (8.51) 16
Obesity II 1 (1.03) 1 (1.06) 2
AHF: Antiurolithic herbal formula, CPL: Commercial polyherbal lithotriptic, BMI: Body mass index
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The study showed significant size reduction both single and multiple 
type stone in AHF group (p<0.05) [Table 4]. Total of differences in AHF 
group greater than CPL group. On multiple type stone, the number 
of stone was also decreased significantly. However, the event was 
not found in CPL group (Table 5). There was a significant difference 
of single stone size between baseline and after 8 weeks intervention 
in both AHF and CPL group. Table 6 shows that the number of single 
and multiple stone was significantly decreased after AFH intervention 
compared to baseline. In contrast, there was no significant difference 
about the number of stone in CPL group. Thus, there was significant 
difference between the two groups at 8th week.
The comparison result between two groups of intervention is shown 
in Fig. 2. In the AHF group, 43.29% of subjects who get herbal formula 
were included in the success category and 34.02% had little decreased 
than baseline. In CPL group, there were 35.10% and 27.66% categorized 
as successfully treatment and little decreased, respectively. 
Both groups showed a significant decrease of VAS at the end of 
intervention (Table 7). The mean of VAS of AHF group subjects was 
54.55±20.24 at baseline and 29.01±17.57 at 4th week. It continued 
decreasing until 18.64±17.68 at 8th week. Using paired samples t-test, 
there was a significant decrease in the degree of pain compared to 
baseline.
The biochemical parameter was observed to evaluate the safety of AHF 
and CPL group. Table 8 shows no abnormalities value in SGOT and SGPT 
levels during intervention between two groups. Despite no statistically 
significant, there was decrease in SGOT levels in AHF group. While SGPT 
levels were decreased significantly at 4th week compared to baseline. 
There were no statistically significant differences in renal and liver 
function with p>0.05. Creatinine and BUN are biochemical parameters 
to assess renal function. Subject who consumed formula had mean 
of creatinine 1.02±0.35mg/dl. It decreased in 1.00±0.30 mg/dl and 
0.98 at 4 and 8 weeks, respectively. While in CPL group, creatinine 
levels tend to persist with 0.84±0.30 mg/dl, 0.85±0.29 mg/dl, and 
0.83±0.28 mg/dl at baseline, 4th week, and 8th week, respectively. Even 
though creatinine level was higher in AHF group than CPL, it was not 
statistically significant. There was no abnormalities potassium level in 
both two groups. It can be concluded that the potassium levels of all 
subjects before, during, and after the intervention of both groups were 
still in normal limits.
Assessed for eligibility : (307)
Excluded (107) : not eligible 
in laboratory and 
radiology screening
randomized (200)






Lost to follow-up (3)
 Discontinued intervention-baseline




Fig. 1: Flowchart of recruitment and enrollment process
Table 2: Urolithiasis characteristics
Characteristics of stone AHF group n (%) CPL group n (%)
Location of stone
Pelvis renalis 85 (85.8) 79 (82.3)
Ureter 9 (9.1) 14 (14.6)
Vesica urinaria 5 (5.1) 3 (3.1)
Type of stone
Single 66 (68) 46 (48.9)
Multiple 31 (32) 48 (51.1)
AHF: Antiurolithic herbal formula, CPL: Commercial polyherbal lithotriptic
Table 3: Comparison between AHF and CPL groups in terms of 
size and number of stone before treatment (baseline)
Size and number stone AHF group CPL group P
Mean±SD Mean±SD
Size of single type stone 10.82±8.19 8.07±5.19 0.073
Size of multiple type stone 11.19±6.08 16.66±15.30 0.283
Number all of stones 1.44±0.97 1.50±0.77 0.656
*p<0.05 significantly differences with confidence interval (CI) 95% of 
independent t-test, AHF: Antiurolithic herbal formula, CPL: Commercial 
polyherbal lithotriptic
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DISCUSSION
Majority of the participants in this study were male. It is consistent 
with other previous studies. Men have greater muscle mass than 
woman that make their risk for urolithiasis is higher compare to 
woman. In addition, testosterone has ability to increase hepatic 
oxalate production in men. Estrogen can prevent the formation of 
oxalate stones because it keeps urine pH alkaline and increases citrate 
levels in urine [12,15]. Another study mentions that the risk ratio 
urolithiasis between male and female is 1.7:1 and 1.3:1 in 1997 and 
2002, respectively [16], whereas the ratio of this study was 1.9:1 and 
1.6:1 in AHF and CPL group, respectively. The ratio both of two groups 
has no statistical difference. The highest age of this study subjects was 
at the age of 45–55 years in two groups. Similar with another study 
that the peak incidence of urolithiasis at the age of 40–60 years old 
[5,17].
A cohort study conducted in the USA showed that there is a close 
relationship between the incidences of urolithiasis with BMI [18]. In 
this study, the number of subjects with BMI more than normal was 
greater than normal weight (>50%).
A study explained that urine pH was inversely proportional to body 
weight (bw) and vice versa. Hamano et al. said the excretion of 
promoting factors in the formation of oxalate stones cause strong 
correlation between obesity and the incidence of urolithiasis [19].
The highest of the prevalence of urolithiasis is located in pelvis renal. 
Other research explained the comparison between the upper and lower 
urinary tract stones was 9:1 [20].
As a result, the herbal formulation can significantly reduce the size 
and number of urolithiasis. In the CPL group, the size of single type 
stones decreased significantly but did not occur in multiple stone. 
While a significantly decrease happened on both of single and 
multiple stones in AHF group. Statistical test results of both two 
groups showed no significant differences in multiple stone reduction, 
whereas it was significant differences in single stone. Regarding 
the number of stones was also significantly decrease in single and 
multiple types in AHF whereas vice versa in CPL group. Thus, the 
comparison of the total difference between AHF and CPL was 1.9:1. 
In other words, formula has the capability to dissolve stones twice 
better than CPL.
Fig. 2: Comparison between two groups of treatment
Table 5: Comparison of size reduction of stone between AHF and CPL group
Type of stone AHF group CPL group
Size reduction (mm)±SD Size reduction (mm)±SD p
Single’s stone 4.53±6.81 0.49±9.57 0.009*
Multiple’s stone 2.99±5.57 3.56±11.14 0.798
*p<0.05 significantly differences with confidence interval (CI) 95% of independent t-test, AHF: Antiurolithic herbal formula, CPL: Commercial polyherbal lithotriptic
Table 6: Number of stone analysis
Type of stone AHF group CPL group
Assesment time Mean (pcs)±SD Mean (pcs)±SD p
Single Baseline 1.00±0.00 1.00±0.00 0.656
4th week 0.62±0.59a 0.96±1.13
Multiple Baseline 2.48±1.27 1.97±0.83 0.036c
8th week 1.72±1.19a 1.58±1.14
a: p<0.05 (CI 95%) significant difference 8th week compared to baseline in the same group, b: p<0.05 (CI 95%) significant difference baseline compared two groups in all 
of the number of stone, c: p<0.05 (CI 95%) significant difference 8th week compared two groups in all of the number of stone, CI: Confidence Interval, AHF: Antiurolithic 
herbal formula, CPL: Commercial polyherbal lithotriptic
Table 7: Comparison of VAS between AHF and CPL group
Day AHF group CPL group p (AHF and 
CPL group)Mean SD Mean SD
Baseline 54.55 20.24 48.19 30.08 0.333
4th week 29.01a 17.57 28.33c 21.81 0.457
8th week 18.64b 17.68 17.35d 18.98 0.200
a: p<0.05 (CI 95%) significant differences 4th week compared to baseline in same 
group, b: p<0.05 (CI 95%) significant differences 8th week compared to baseline 
in same group, c: p<0.05 (CI 95%) significant differences 4th week compared 
to baseline between two groups, d: p<0.05 (CI 95%) significant differences 8th 
week compared to baseline between two groups, AHF: Antiurolithic herbal 
formula, CPL: Commercial polyherbal lithotriptic, VAS: Visual analog scale
Table 4: Size of single and multiple type stone in AHF and CPL group
Type of stone AHF group CPL group
Weeks Mean (mm)±SD p Mean (mm)±SD P
Single Baseline 10.82±8.19 0.0001* 8.07±5.98 0.006*
4th week 6.28±8.12 7.58±10.47
Multiple Baseline 11.1±96.08 0.007* 16.66±15.30 0.071
8th week 8.1±6.46 13.10±14.69
*p<0.05 swap independent t-test with “paired t-test”, AHF: Antiurolithic herbal formula, CPL: Commercial polyherbal lithotriptic
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Seeing the results, it can be explained that the herbal formula for 
urolithiasis consists of S. arvensis L. leaves, O. stamineus Benth leaves, 
S. crispus B1 leaves, I. cylindrica roots, turmeric, temulawak, and 
meniran can reduce significantly size and number of stones. CPL group 
has a similar composition with herbal formula, but there are several 
components that are not present in the CPL but present in herbal 
formula. Moreover, the difference in solvent might be the other reasons 
for different capability. Several studies have suggested that water 
solvents are better than alcohol for plants which capable to dissolve 
urolithiasis. The potency of S. arvensis to dissolve kidney stones by 
water extracts is better than alcohol extracts [21].
The tempuyung leave (S. arvensis L.) contains soluble compounds 
in water such as mineral, carbohydrate, and glycoside 
(luteolin-7-O-glukosida and apigenin-7-O-glukosida) [22]. Other study 
revealed that S. arvensis L. Infuse (0.50%) at dose of 8 ml/kg bw have 
diuretic effect 29.60% in male rabbit. Tempuyung is enriched with 
high kalium and natrium that useful to maintain electrolyte balance 
in kidney. Kalium can remove calcium in oxalate stone and make 
salt soluble compound in urine [23]. The majority of risk factor in 
pathogenesis urolithiasis is hyperoxaluria [24].
Diuretic activity of O. stamineus at dose of 50 mg/kg bw equivalent 
with HCT at dose of 10 mg/kg bw [25]. It has ability to prevent forming 
calcium crystal [26].
Kejibeling leaves (S. crispus B1) can solve nephrolithiasis and 
vesicolithiasis due to it has strong diuretic activity of kalium which can 
expulse calcium oxalate stone [27].
Potential action of herbal formulation might work in synergism 
process including diuretic, antimicrobial, antioxidant, anti-
inflammatory, antispasmodic, litholytic, and antilithogenic activities 
of its ingredients [28]. Several reviews explained that the mechanism 
of action beside diuretic for urolithiasis treatment is action to increase 
urolithiasis inhibitor by elevating urinary citrate excretion. In addition, 
antilithogenic effect with the effect of by decreasing urinary calcium and 
oxalate, thus reducing the risk of stone formation [29]. Antimicrobial 
and antioxidant are also one of antilithogenic effect to prevent stone 
formation [4]. Similarly, the previous study reported the relationship 
between free radicals and nephrolithiasis in which causes renal tubular 
cell damage, thus stimulates crystal formation [30]. Free radicals play 
an important role in stone formation by increasing protein-bound 
carbonyl groups [31]. Lipid peroxidation can cause urolithiasis by 
inducing oxidatively damaged protein which is released by damage 
cell [32,30]. These proteins can reduce inhibitor factors or increase the 
promoter of the crystallization process [30]. Medicinal plants which are 
enriched with antioxidants can prevent calcium oxalate precipitation 
in the kidneys and reduce oxalate excretion [33]. In this study, the 
presence of C. longa and C. xanthorrhiza besides has the ability as 
antioxidants as well as antimicrobial.
The safety of these herbal formulas is proved by normal biochemical 
parameters value. In addition, there is no significant difference 
between before and after the intervention in liver and renal function 
parameters. In AHF group, there was a significant decrease in SGPT 
which probably due to the hepatoprotector effect of C. xanthorrhiza and 
I. cylindrical [34,35].
CONCLUSION
The results of this study indicated that AHF is safe and effective in the 
treatment of urolithiasis.
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